Fulcrum Therapeutics Slips Despite Promising Trial Results

Fulcrum Therapeutics shares are trading lower despite announcing positive results from their Phase 1b PIONEER trial for pociredir in sickle cell disease, as uncertainties over future development and financial prospects weigh on investor sentiment.